Insider

Merck & Co., Inc.

MRK Health Care · 3 analyses · 4 expectations tracked

Merck reported $18.1B in revenue (+4.7% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 4 open management expectations for this company. 1 insider sale recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Зміни в раді директорів Merck та операції з акціями топменеджера

Член ради директорів Merck & Co., Inc. Томас Г. Глокер планує піти у відставку під час щорічних зборів акціонерів у травні 2027 року. Компанія підтвердила, що це рішення не пов'язане з жодними розбіжностями щодо її операцій чи політики.

· Merck & Co., Inc.
What changed

Merck released third-quarter 2026 results

Merck & Co., Inc. reported third-quarter 2026 results with earnings per share (EPS) of $2.04 under generally accepted accounting principles (GAAP) and $2.49 on a non-GAAP basis. The quarter included a $400 million one-time charge for a new license agreement and lower revenue from the Koselugo alliance, which followed a 2025 contract restructuring.

· Merck & Co., Inc.
What changed

Merck appointed Paul J. Diaz as a member of the board of directors

On October 13, 2026 Merck & Co., Inc. announced that Paul J. Diaz, managing partner of Cressey & Company, will join the board of directors on November 1, 2026, increasing the board to 14 members; he will serve on the audit and research committees and will receive standard compensation without conflicting agreements.

· Merck & Co., Inc.

Company history

October 2026

Merck & Co., Inc. appointed a new director, released third-quarter 2026 financial results, and reported several clinical and regulatory developments in October 2026.

  • On October 13, 2026, the company announced that Paul J. Diaz was appointed to the Board of Directors effective November 1, 2026, and also named to the Board's Audit and Research Committees. Source 1 · Source 2
  • On October 15, 2026, the company filed a notice regarding the removal of its 1.875% Notes due 2026. Source
  • On October 29, 2026, the company reported third-quarter 2026 results, including GAAP EPS of $2.04 and non-GAAP EPS of $2.49. Source 1 · Source 2
  • On October 29, 2026, the company announced a global license agreement with SciBrunch for the investigational oral KRAS G12D inhibitor SPR2015, incurring a $400 million R&D charge. Source
  • On October 29, 2026, the company noted FDA approval of WELIREG plus Lenvima for renal cell carcinoma and European Commission approval of KEYTRUDA plus Padcev for bladder cancer. Source
  • On October 29, 2026, Japan's Ministry of Health, Labor and Welfare approved the subcutaneous injection KEYJECT for all KEYTRUDA indications approved in Japan. Source
  • On October 29, 2026, the company announced FDA acceptance of an sBLA for ENFLONSIA and a label update for WINREVAIR including data from the Phase 3 HYPERION trial. Source
  • On October 29, 2026, the company announced the voluntary withdrawal of the Biologics License Application for ifinatamab deruxtecan in collaboration with Daiichi Sankyo. Source
  • On October 29, 2026, the company presented results from the Phase 2b/3 BRUNELLO trial for Remigromig and announced positive Phase 2b results for Tulisokibart in patients with moderate to severe Hidradenitis Suppurativa. Source
  • On October 29, 2026, the company recorded one-time R&D charges of $9.0 billion for the acquisition of Cidara Therapeutics, Inc. and $5.7 billion for the acquisition of Terns Pharmaceuticals, Inc. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 4, 2026. SEC

LatestEarlierChange
Revenue quarter$18.1B$17.3B+4.7%
Net income quarter$5.1B$5.8B-12.4%
Diluted EPS quarter$2.04$2.32-12.1%
Dividends per share quarter$0.85$0.81+4.9%
Operating cash flow year to date$15.8B$13.6B+16.4%
Cash and cash equivalents balance$9.6B$14.6B-34.4%
Long-term debt balance$49.7B$46.8B+6.3%

Next results expected around February 3, 2027 (estimate: the quarter ending about December 30, 2026 plus the 35 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

15.6Q4 '24*15.5Q1 '2515.8Q2 '2517.3Q3 '2516.4Q4 '25*16.3Q1 '2616.6Q2 '2618.1Q3 '26
Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Merck & Co., Inc. MRK$18.1B+4.7%—
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The Company established a goal to reach 100 million people with access solutions that close gaps in care by 2030.

    Said October 29, 2026 · Period named: 2030 · Source · Our article

    Not yet checked against later reports.

  • For full-year 2026, the company expects worldwide sales to be between $66.8 billion and $67.3 billion.

    Said October 29, 2026 · Period named: Full-Year 2026 · Source · Our article

    Not yet checked against later reports.

  • The Company anticipates full-year 2026 sales to be between $66.8 billion and $67.3 billion.

    Said October 29, 2026 · Period named: full-year 2026 · Source · Our article

    Not yet checked against later reports.

  • The Company expects full-year 2026 non-GAAP EPS to be between $2.77 and $2.82.

    Said October 29, 2026 · Period named: full-year 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 15, 2026Removal of a security from listing (Form 25)25-NSE
October 13, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 12, 2026Richard R. DeLucaSale58,185$148.01$8,611,875SEC
November 12, 2026Richard Robert Deluca JrPlanned sale58,185—$8,611,875SEC
November 2, 2026David M WilliamsPlanned sale21,359—$3,185,464SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock228,073,244$33,141,323,200+0.5%Q3 2026
State Street121,422,392$17,745,130,704+0.8%Q3 2026
Wellington Management71,664,541$10,413,574,452-16.9%Q3 2026
Geode Capital Management61,565,702$8,933,217,060+1.4%Q3 2026
Fidelity (FMR)46,222,051$6,716,526,284+1.7%Q3 2026
Norges Bank (Norway's sovereign fund)36,983,784$4,752,416,244—Q2 2026
Citadel Advisors3,323,725$482,970,480+71.9%Q3 2026
Millennium Management1,743,246$253,311,076+210.6%Q3 2026
D. E. Shaw & Co.808,713$117,514,086-70.5%Q3 2026
Capital Research Global Investors693,817$100,818,548-64.0%Q3 2026
Two Sigma Investments93,116$13,530,686+91.5%Q3 2026
Bridgewater Associates39,293$5,709,666+29.9%Q3 2026
T. Rowe Price26,603,959$3,865,822+43.7%Q3 2026
Renaissance Technologies4,357$632,802—Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.